Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Accounts Payables: 2021-2024

Historic Accounts Payables for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $2.0 million.

  • Kiniksa Pharmaceuticals International's Accounts Payables fell 26.15% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year decrease of 26.15%. This contributed to the annual value of $2.0 million for FY2024, which is 75.27% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Accounts Payables of $2.0 million as of FY2024, which was down 75.27% from $8.2 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Accounts Payables registered a high of $8.2 million during FY2023, and its lowest value of $1.9 million during FY2021.
  • In the last 3 years, Kiniksa Pharmaceuticals International's Accounts Payables had a median value of $7.9 million in 2022 and averaged $6.1 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Accounts Payables skyrocketed by 322.86% in 2022, and later tumbled by 75.27% in 2024.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Accounts Payables (Yearly) stood at $1.9 million in 2021, then soared by 322.86% to $7.9 million in 2022, then grew by 4.39% to $8.2 million in 2023, then tumbled by 75.27% to $2.0 million in 2024.